Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Metrics to compare | AUTL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAUTLPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −2.7x | −0.6x | |
PEG Ratio | −0.09 | −0.20 | 0.00 | |
Price/Book | 1.2x | 2.0x | 2.6x | |
Price / LTM Sales | 14.0x | 7.9x | 3.3x | |
Upside (Analyst Target) | - | 164.6% | 39.1% | |
Fair Value Upside | Unlock | 13.1% | 5.4% | Unlock |